Rubina Pal joined CCS in 2023 and is responsible for providing strategic direction and leadership in process and analytical development for cell and gene therapy products. She also oversees the Houston facility operations. Previously, she has led similar functions at Talaris Therapeutics, Atara Biotherapeutics, and FCS Laboratory and brings her expertise in shaping analytical and control strategies for cell therapy, encompassing method development, qualification, validation, transfer, product stability, and technical documentation.
With a background spanning CRO and biotech sectors since 2014, Rubina offers development insights across the entire drug product lifecycle, from pre-clinical stages to commercialization. Notably, she played a key role in the analytical package for Ebvallo™, the first approved allogeneic T cell immunotherapy. Certified by the American Society of Clinical Pathologists as a Specialist in Cytometry (SCYM) and holding a doctoral degree in cell biology from St. George’s, University of London, Rubina is passionate about advancing innovative solutions for our clientele and patients.